Aug 31 (Reuters) – Eli Lilly said on Monday it would acquire privately held Merida Biosciences for up to $2.88 billion in cash, expanding its efforts to develop treatments for immunity-related and allergic diseases.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Leroy Leo)
Comments